Frontiers
US$ 23.94
glp 1 agonists in development Evolution of GLP‐1 Receptor for Diabetes Treatment GLP-1 Receptor Agonist Market Growth
Description
The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes
Ozempic is the hottest drug on the market for weight loss
The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
These products are not intended to diagnose, treat, cure, or prevent any disease
